Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T.SCOTTSDALE, Ariz., Jan. 23,…
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports…
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC)…
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor…
Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE)…
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the…
LONDON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase…
Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented…
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of…